PCYC up +2.51% percent Today $PCYC High is at 142.00 and the Low 137.50 with current volume of 224,600.
Recent News posted below.
Pharmacyclics Inc PCYC other info.
http://investorshangout.com/Pharmacyclics-Inc-PCYC-55069/
PCYC Pharmacyclics Inc Recent Headline News
Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Wed Nov 12, 4:38PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $133.66 to a high of $139.25. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $136.11 on volume of 797,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PCYC: 140.59 (+3.22)
Uptrend Call Working As Pharmacyclics Stock Rises 18.2% (PCYC)
Comtex SmarTrend(R) - Wed Nov 12, 11:12AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on October 21st, 2014 at $115.55. In approximately 3 weeks, Pharmacyclics has returned 18.21% as of today's recent price of $136.58.
PCYC: 140.59 (+3.22)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.90 (-0.02), CRIS: 1.33 (+0.03), IMMU: 3.97 (+0.08), PCYC: 140.59 (+3.22), ONCY: 0.80 (-0.04), PFE: 30.60 (+0.18), LLY: 67.95 (+0.55), BMY: 58.06 (-0.55), GSK: 45.85 (+0.23), JNJ: 109.18 (+0.43), SNTA: 3.43 (+0.07), NVS: 94.32 (+1.66), XLRN: 35.37 (+1.58), ARRY: 3.84 (+0.03), CELGZ: 3.15 (+0.02), EXEL: 1.87 (+0.06)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), GILD: 105.09 (-1.81), AZN: 74.84 (+0.58), GSK: 45.85 (+0.23), BMY: 58.06 (-0.55), CELG: 108.80 (+0.55)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.58 (+0.39), PCYC: 140.59 (+3.22), CLDX: 15.08 (+0.27), INCY: 72.25 (+0.38), BIND: 10.02 (+0.04), CELG: 108.80 (+0.55), OMER: 19.65 (-0.06), VSTM: 9.49 (+0.12), GILD: 105.08 (-1.82), OGXI: 2.17 (-0.01), ANTH: 1.85 (+0.03), NVAX: 5.28 (+0.04)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 64.94 (+0.10), JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), SHPG: 202.50 (+1.99), MRK: 59.83 (+0.52), AMGN: 161.98 (+0.05)
After Yesterday's Rally of 4.65% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 4:27PM CST
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $130.29 to a high of $137.42. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $136.89 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PCYC: 140.59 (+3.22)
IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting
PR Newswire - Thu Nov 06, 8:09AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA from December 6 - 9, 2014. IMBRUVICA clinical and pre-clinical data will be featured in at least 37 abstracts, of which 17 are from company-sponsored clinical and non-clinical studies. Eight abstracts were selected for oral presentation.
PCYC: 140.59 (+3.22)
Keith Lui Joins Versartis to Lead Global Marketing Efforts
GlobeNewswire - Thu Nov 06, 7:42AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced that Keith L. Lui has joined the company as Vice President, Marketing. Mr. Lui will report to Versartis Chief Executive Officer Jeffrey L. Cleland, PhD, to lead the development and execution of the brand marketing process including global marketing launch plan activities for the Company's lead product candidate, VRS-317.
VSAR: 19.39 (-0.14), PCYC: 140.59 (+3.22)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.93 (-0.09), PCYC: 140.59 (+3.22), PSTI: 2.65 (+0.02), NBS: 5.40 (+0.07), ALDR: 15.92 (-0.06), IDRA: 2.58 (+0.02), SGEN: 38.15 (+0.35), JAZZ: 176.25 (+2.72), ALXN: 194.44 (+0.75), KMDA: 3.44 (-0.06), ATHX: 1.43 (unch), NVS: 94.32 (+1.66)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), AZN: 74.84 (+0.58), AMAG: 34.85 (-0.08)
Pharmacyclics Shares Up 14.1% Since SmarTrend's Buy Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on October 21st, 2014 at $115.55. In approximately 2 weeks, Pharmacyclics has returned 14.08% as of today's recent price of $131.81.
PCYC: 140.59 (+3.22)
Pharmacyclics' (PCYC) CEO Robert Duggan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:01PM CST
PCYC: 140.59 (+3.22)
Pharmacyclics tops Street 3Q forecasts
Automated Insights - Tue Nov 04, 3:30PM CST
SUNNYVALE, Calif. (AP) _ Pharmacyclics Inc. (PCYC) on Tuesday reported third-quarter net income of $41.4 million.
PCYC: 140.59 (+3.22)
Pharmacyclics beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:21PM CST
PCYC: 140.59 (+3.22)
Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update
PR Newswire - Tue Nov 04, 3:05PM CST
Pharmacyclics, Inc. (the "Company"
(NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014, as well as commercial, regulatory and clinical updates.
PCYC: 140.59 (+3.22)
AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers
PR Newswire - Tue Nov 04, 1:32PM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers.
PCYC: 140.59 (+3.22)
AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors
PR Newswire - Tue Nov 04, 10:00AM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.
PCYC: 140.59 (+3.22)
AstraZeneca teams up with Pharmacyclics and Janssen in cancer combo
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 8:28AM CST
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), AZN: 74.84 (+0.58)
AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers
PR Newswire - Tue Nov 04, 7:00AM CST
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development LLC ("Janssen" today announced they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech, Inc. The study will assess the combination as a treatment for patients with hematologic cancers including Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, which are investigational uses for both compounds.
PCYC: 140.59 (+3.22)
Recent News posted below.
Pharmacyclics Inc PCYC other info.
http://investorshangout.com/Pharmacyclics-Inc-PCYC-55069/
PCYC Pharmacyclics Inc Recent Headline News
Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Wed Nov 12, 4:38PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $133.66 to a high of $139.25. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $136.11 on volume of 797,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PCYC: 140.59 (+3.22)
Uptrend Call Working As Pharmacyclics Stock Rises 18.2% (PCYC)
Comtex SmarTrend(R) - Wed Nov 12, 11:12AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on October 21st, 2014 at $115.55. In approximately 3 weeks, Pharmacyclics has returned 18.21% as of today's recent price of $136.58. PCYC: 140.59 (+3.22)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.90 (-0.02), CRIS: 1.33 (+0.03), IMMU: 3.97 (+0.08), PCYC: 140.59 (+3.22), ONCY: 0.80 (-0.04), PFE: 30.60 (+0.18), LLY: 67.95 (+0.55), BMY: 58.06 (-0.55), GSK: 45.85 (+0.23), JNJ: 109.18 (+0.43), SNTA: 3.43 (+0.07), NVS: 94.32 (+1.66), XLRN: 35.37 (+1.58), ARRY: 3.84 (+0.03), CELGZ: 3.15 (+0.02), EXEL: 1.87 (+0.06)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), GILD: 105.09 (-1.81), AZN: 74.84 (+0.58), GSK: 45.85 (+0.23), BMY: 58.06 (-0.55), CELG: 108.80 (+0.55)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.58 (+0.39), PCYC: 140.59 (+3.22), CLDX: 15.08 (+0.27), INCY: 72.25 (+0.38), BIND: 10.02 (+0.04), CELG: 108.80 (+0.55), OMER: 19.65 (-0.06), VSTM: 9.49 (+0.12), GILD: 105.08 (-1.82), OGXI: 2.17 (-0.01), ANTH: 1.85 (+0.03), NVAX: 5.28 (+0.04)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 64.94 (+0.10), JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), SHPG: 202.50 (+1.99), MRK: 59.83 (+0.52), AMGN: 161.98 (+0.05)
After Yesterday's Rally of 4.65% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 4:27PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $130.29 to a high of $137.42. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $136.89 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PCYC: 140.59 (+3.22)
IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting
PR Newswire - Thu Nov 06, 8:09AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA from December 6 - 9, 2014. IMBRUVICA clinical and pre-clinical data will be featured in at least 37 abstracts, of which 17 are from company-sponsored clinical and non-clinical studies. Eight abstracts were selected for oral presentation.
PCYC: 140.59 (+3.22)
Keith Lui Joins Versartis to Lead Global Marketing Efforts
GlobeNewswire - Thu Nov 06, 7:42AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced that Keith L. Lui has joined the company as Vice President, Marketing. Mr. Lui will report to Versartis Chief Executive Officer Jeffrey L. Cleland, PhD, to lead the development and execution of the brand marketing process including global marketing launch plan activities for the Company's lead product candidate, VRS-317.
VSAR: 19.39 (-0.14), PCYC: 140.59 (+3.22)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.93 (-0.09), PCYC: 140.59 (+3.22), PSTI: 2.65 (+0.02), NBS: 5.40 (+0.07), ALDR: 15.92 (-0.06), IDRA: 2.58 (+0.02), SGEN: 38.15 (+0.35), JAZZ: 176.25 (+2.72), ALXN: 194.44 (+0.75), KMDA: 3.44 (-0.06), ATHX: 1.43 (unch), NVS: 94.32 (+1.66)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), AZN: 74.84 (+0.58), AMAG: 34.85 (-0.08)
Pharmacyclics Shares Up 14.1% Since SmarTrend's Buy Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ
CYC) on October 21st, 2014 at $115.55. In approximately 2 weeks, Pharmacyclics has returned 14.08% as of today's recent price of $131.81. PCYC: 140.59 (+3.22)
Pharmacyclics' (PCYC) CEO Robert Duggan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:01PM CST
PCYC: 140.59 (+3.22)
Pharmacyclics tops Street 3Q forecasts
Automated Insights - Tue Nov 04, 3:30PM CST
SUNNYVALE, Calif. (AP) _ Pharmacyclics Inc. (PCYC) on Tuesday reported third-quarter net income of $41.4 million.
PCYC: 140.59 (+3.22)
Pharmacyclics beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:21PM CST
PCYC: 140.59 (+3.22)
Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update
PR Newswire - Tue Nov 04, 3:05PM CST
Pharmacyclics, Inc. (the "Company"
(NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014, as well as commercial, regulatory and clinical updates. PCYC: 140.59 (+3.22)
AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers
PR Newswire - Tue Nov 04, 1:32PM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers.
PCYC: 140.59 (+3.22)
AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors
PR Newswire - Tue Nov 04, 10:00AM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.
PCYC: 140.59 (+3.22)
AstraZeneca teams up with Pharmacyclics and Janssen in cancer combo
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 8:28AM CST
JNJ: 109.18 (+0.43), PCYC: 140.59 (+3.22), AZN: 74.84 (+0.58)
AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers
PR Newswire - Tue Nov 04, 7:00AM CST
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development LLC ("Janssen"
today announced they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech, Inc. The study will assess the combination as a treatment for patients with hematologic cancers including Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, which are investigational uses for both compounds. PCYC: 140.59 (+3.22)
